Design, synthesis and evaluation of belinostat analogs as histone deacetylase inhibitors

被引：5

作者：

Zhang, Jie-Huan ^{[1
]}

Mottamal, Madhusoodanan ^{[3
,4
]}

Jin, Hai-Shan ^{[1
]}

Guo, Shanchun ^{[3
,4
]}

Gu, Yan ^{[1
]}

Wang, Guangdi ^{[3
,4
]}

Zhao, Li-Ming ^{[1
,2
]}

机构：

[1] Jiangsu Normal Univ, Sch Chem & Mat Sci, Xuzhou 221116, Jiangsu, Peoples R China

[2] Guangxi Normal Univ, State Key Lab Chem & Mol Engn Med Resources, Guilin 541004, Guangxi, Peoples R China

[3] Xavier Univ Louisiana, RCMI Canc Res Ctr, New Orleans, LA 70125 USA

[4] Xavier Univ Louisiana, Dept Chem, New Orleans, LA 70125 USA

来源：

FUTURE MEDICINAL CHEMISTRY | 2019年 / 11卷 / 21期

关键词：

anticancer activities; drug design; molecular docking; structure-activity relationship; synthesis; HYDROXAMIC ACID; BIOLOGICAL EVALUATION; DERIVATIVES;

D O I：

10.4155/fmc-2018-0587

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Aim: Histone deacetylase (HDAC) is an attractive target for antitumor therapy. Therefore, the development of novel HDAC inhibitors is warranted. Materials & methods: A series of HDAC inhibitors based on N-hydroxycinnamamide fragment was designed as the clinically used belinostat analog using amide as the connecting unit. All target compounds were evaluated for their in vitro HDAC inhibitory activities and some selected compounds were tested for their antiproliferative activities. Conclusion: Among them, compound 7e showed an IC50 value of 11.5 nM in inhibiting the HDAC in a pan-HDAC assay, being the most active compound of the series.

引用

页码：2765 / 2778

页数：14

共 31 条

[1] The Cambridge Structural Database: a quarter of a million crystal structures and rising
Allen, FH
[J]. ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1): : 380 - 388
[2] [Anonymous], 2017, SCHROD REL 2017 1 GL
[3] Cell-targeted cytotoxics: a new generation of cytotoxic agents for cancer treatment
Bailly, Christian
[J]. PHYTOCHEMISTRY REVIEWS, 2014, 13 (01) : 171 - 181
[4] Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis
Brameld, Ken A.
Kuhn, Bernd
Reuter, Deborah C.
Stahl, Martin
[J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2008, 48 (01) : 1 - 24
[5] Chidamide in the treatment of peripheral T-cell lymphoma
Chan, Thomas S.
Tse, Eric
Kwong, Yok-Lam
[J]. ONCOTARGETS AND THERAPY, 2017, 10 : 347 - 352
[6] Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors
Chen, Chen
Hou, Xuben
Wang, Guohua
Pan, Wenyan
Yang, Xinying
Zhang, Yingkai
Fang, Hao
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 133 : 11 - 23
[7] Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilide hydroxamic acid and trichostatin A
Codd, Rachel
Braich, Najwa
Liu, Joe
Soe, Cho Zin
Pakchung, Amalie A. H.
[J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (04) : 736 - 739
[8] Novel sulfonamide derivatives as inhibitors of histone deacetylase
Finn, PW
Bandara, M
Butcher, C
Finn, A
Hollinshead, R
Khan, N
Law, N
Murthy, S
Romero, R
Watkins, C
Andrianov, V
Bokaldere, RM
Dikovska, K
Gailite, V
Loza, E
Piskunova, I
Starchenkov, I
Vorona, M
Kalvinsh, I
[J]. HELVETICA CHIMICA ACTA, 2005, 88 (07) : 1630 - 1657
[9] Panobinostat: First Global Approval
Garnock-Jones, Karly P.
[J]. DRUGS, 2015, 75 (06) : 695 - 704
[10] OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
Harder, Edward
Damm, Wolfgang
Maple, Jon
Wu, Chuanjie
Reboul, Mark
Xiang, Jin Yu
Wang, Lingle
Lupyan, Dmitry
Dahlgren, Markus K.
Knight, Jennifer L.
Kaus, Joseph W.
Cerutti, David S.
Krilov, Goran
Jorgensen, William L.
Abel, Robert
Friesner, Richard A.
[J]. JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2016, 12 (01) : 281 - 296

← 1 2 3 4 →